Given the importance of the contentious issues and the importance of the outcome to policyholders – particularly small and medium-sized enterprises – the regulator has set an ambitious timetable for the organisation and solution of the ACF`s action. With the agreement of the participating insurers and the High Court, the ACF was able to achieve its goal of taking legal action within six weeks of filing the application. “Our legal actions are intended to provide all policyholders and insurers with both clarity and safety to all those involved in these BI litigations. We believe that this is also the fastest way to achieve this clarity, and by covering several policies and insurers, it will also be the most useful in the whole market. The identification of a representative sample of policies and the agreement of the insurers that forced them to participate in this procedure is an important step in bringing the case to court. On June 1, the Financial Conduct Authority (FCA) provided detailed information on insurers who were invited to participate in their trial project before the British High Court on Interruption of Service Insurance (BI) and who have already reached a framework agreement with the FCA on the trial process and schedule. Insurers include Arch Insurance Limited (UK), Argenta Syndicate Management Limited, Ecclesiastical Insurance Office Plc, Hiscox Insurance Company Limited, MS Amlin Underwriting Limited, QBE UK Limited, Royal-Sun Alliance Insurance plc and Zurich Insurance Plc. The new “Facts Adopted” document contains factual scenarios that some parties will use in the study to illustrate their views on how reports are triggered. These were born from the previous document “Supposed Facts” as a result of the discussion and agreement between the parties. On its website, the FCA identifies the eight insurers who have entered into a framework contract with the FCA and who have agreed to be accused in the event of a test. Eight other insurers are listed on the website because they use at least one of the guideline formulations presented in the sample, but are not directly included in the trial case.